GMAB - Company ID 0001434265
GENMAB A/S trades as GMAB and has a market capitalization of $16.27 B, making it the #697 largest US-listed company by market value. This page tracks GENMAB A/S through 540 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-05-29
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| 6-K | - | 2026-05-13 |
| 6-K | - | 2026-05-12 |
| 6-K | - | 2026-05-08 |
| 6-K | - | 2026-05-07 |
| 6-K | - | 2026-04-17 |
| 6-K | - | 2026-04-17 |
| 6-K | - | 2026-04-14 |
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress - Genmab A/S
Genmab A/S has published its Articles of Association - Genmab A/S
Transforming the treatment of cancer and other serious diseases
Transforming the treatment of cancer and other serious diseases
Transforming the treatment of cancer and other serious diseases
The largest companies sharing GENMAB A/S's SEC industry classification (pharmaceutical preparations).
GENMAB A/S (GMAB) has a market capitalization of $16.27 B as of 2026-05-29, ranking #697 among US-listed companies.